miR-301a-3p promotes hepatic stellate cells activation and liver fibrogenesis via regulating PTEN/PDGFR-β-Reference-Cited by-同舟云学术

miR-301a-3p promotes hepatic stellate cells activation and liver fibrogenesis via regulating PTEN/PDGFR-β

Published:2022-09 Issue: Volume:110 Page:109034
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Chen Xin,Zhu Sai,Chen Si-Yu,Wang Jia-Nan,Sun Li-Jiao,Tao Shan-Min,Li Xiao-Feng,Li Hai-Di,Sun Ying-Yin,Xu Chuan-Hui,Suo Xiao-Guo,Ji Ming-Lu,Huang Cheng,Meng Xiao-Ming,Li Jun

Publisher

Elsevier BV

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference41 articles.

1. Liver fibrosis;Bataller;J. Clin. Invest.,2005

2. SCARNA10, a nuclear-retained long non-coding RNA, promotes liver fibrosis and serves as a potential biomarker;Zhang;Theranostics,2019

3. Protease-activated receptor 2 promotes experimental liver fibrosis in mice and activates human hepatic stellate cells;Knight;Hepatology,2012

4. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver;Friedman;Physiol. Rev.,2008

5. Origin of myofibroblasts in the fibrotic liver in mice;Iwaisako;Proc. Natl. Acad. Sci. USA,2014

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Volatile oil of Angelica sinensis Radix improves cognitive function by inhibiting miR-301a-3p targeting Ppp2ca in cerebral ischemia mice;Journal of Ethnopharmacology;2024-03

2. miR-324-3p Suppresses Hepatic Stellate Cell Activation and Hepatic Fibrosis Via Regulating SMAD4 Signaling Pathway;Molecular Biotechnology;2024-02-26

3. N6-methyladenosine-modified circIRF2, identified by YTHDF2, suppresses liver fibrosis via facilitating FOXO3 nuclear translocation;International Journal of Biological Macromolecules;2023-09

4. The role of miRNAs in liver diseases: Potential therapeutic and clinical applications;Pathology - Research and Practice;2023-03

5. Association of circulating miRNAS in patients with Alstrőm and Bardet-Biedl syndromes with clinical course parameters;Frontiers in Endocrinology;2022-11-25